(Q38268590)

1 September 2017

1 reference

title

Weight gain and antipsychotics: a drug safety review (English)

1 reference

1 September 2017

1 reference

Richard Musil

1

1 reference

1 September 2017

Michael Obermeier

series ordinal

2

1 reference

1 September 2017

Paul Russ

series ordinal

3

1 reference

1 September 2017

Michael Hamerle

series ordinal

4

1 reference

1 September 2017

language of work or name

English

0 references

publication date

15 November 2014

1 reference

Expert Opinion on Drug Safety

1 September 2017

published in

1 reference

1 September 2017

volume

14

1 reference

1 September 2017

issue

1

1 reference

1 September 2017

page(s)

73-96

1 reference

Pharmacological management of atypical antipsychotic-induced weight gain.

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Pharmacotherapy of bipolar disorder in children and adolescents: recent progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Medication adherence and subjective weight perception in patients with first-episode psychotic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Obesity and coronary risk in patients treated with second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Genetics of antipsychotic-induced weight gain: update and current perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Antipsychotic drugs opposite to metabolic risk: neurotransmitters, neurohormonal and pharmacogenetic mechanisms underlying with weight gain and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Atypical antipsychotic-induced weight gain: insights into mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Weight gain in antipsychotic-naive patients: a review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Age-dependent metabolic effects of second-generation antipsychotics in second-generation antipsychotic-naïve French Canadian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Schizophrenia: women bear a disproportionate toll of antipsychotic side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Weight change from 3-year observational data: findings from the worldwide schizophrenia outpatient health outcomes database

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Safety of amisulpride in combination with antidepressants under common clinical practice conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Switching to aripiprazole as a strategy for weight reduction: a meta-analysis in patients suffering from schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Short-term safety and pharmacokinetic profile of asenapine in older patients with psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Combination therapy for manic phases: a critical review of a common practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Non-neurological and metabolic side effects in the Cost Utility of the Latest Antipsychotics in Schizophrenia Randomised Controlled Trial (CUtLASS-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Metabolic parameters in patients treated with olanzapine or other atypical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Olanzapine-fluoxetine combination for the treatment of bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Are antipsychotics effective for the treatment of anorexia nervosa? Results from a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Atypical antipsychotics and anorexia nervosa: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

The effect of atypical antipsychotic medications in individuals with anorexia nervosa: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Effect of olanzapine orally disintegrating tablet versus oral standard tablet on body weight in patients with schizophrenia: a randomized open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Paliperidone for irritability in adolescents and young adults with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Safety of low doses of quetiapine when used for insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Double-blind placebo-controlled trial of quetiapine in anorexia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

A comparison of risperidone-induced weight gain across the age span

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

A head-to-head comparison of sertindole and risperidone on metabolic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Sertindole in the long-term treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of pfizer-initiated clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Changes in body weight and psychotropic drugs: a systematic synthesis of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Weight gain and lipid-glucose profiles among patients taking antipsychotic medications: comparisons for prescriptions administered using algorithms versus usual care

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Rate of weight gain and cardiometabolic abnormalities in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Bridging the gap from evidence to policy and practice: reducing the progression to metabolic syndrome for children and adolescents on antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Weight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, co

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Safety of olanzapine use in adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Clozapine: a review of clinical practice guidelines and prescribing trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Efficacy of metformin for prevention of weight gain in psychiatric populations: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Considering metformin in cardiometabolic protection in psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders: results from a 12-month, real-world study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Weight gain associated with taking psychotropic medication: an integrative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

A behavioral weight-loss intervention in persons with serious mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

The obesity risk gene FTO influences body mass in chronic schizophrenia but not initial antipsychotic drug-induced weight gain in first-episode patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

A review of FDA-approved treatment options in bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

The association between weight change and symptom reduction in the CATIE schizophrenia trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Efficacy and safety of olanzapine in the treatment of Japanese patients with bipolar I disorder in a current manic or mixed episode: a randomized, double-blind, placebo- and haloperidol-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: a 3-week, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Changes in weight and body mass index during treatment with melperone, clozapine and typical neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Tolerability and efficacy of paliperidone ER compared to olanzapine in the treatment of schizophrenia: A randomized, double-blind, multicentric trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Flexible dosing with paliperidone ER in the treatment of patients with acutely exacerbated schizophrenia: results from a single-arm, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.974549

10.1517/14740338.2015.974549

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference